Innovative approach to assessing effectiveness of anti-cancer drugs
27 Feb 2015
Manchester scientists have a developed a new method to monitor the effect of anti-cancer drugs on very rare leukaemia stem cells. The approach potentially allows doctors to screen patients and personalise their treatment.
The recent development of novel agents has improved outcomes for patients with chronic myeloid leukaemia (CML). These so-called tyrosine kinase inhibitors (TKIs) target abnormal proteins caused by commonly found genetic mutations in CML patients. However, the existence of treatment-resistant cancer stem cells – cells that are able to repeatedly renew the leukaemia cell population – is one way that many patients experience disease recurrence when treatment stops.
Any new drug must therefore be tested on such stem cells, but unfortunately they are only found in very low numbers and are identified by certain cell surface markers. Now researchers at The University of Manchester – part of the Manchester Cancer Research Centre – have tested a way to monitor the effect of drugs on small samples of cells.
Professor Tony Whetton, head of the Stem Cell and Leukaemia Proteomics Laboratory who led the study, said: “Current techniques require greater numbers of cells in order to detect changes caused by TKIs. Our study investigated the potential of a new technology platform that can identify changes in very small cell numbers.”
The research team looked at an antibody-based approach to detect structural changes in certain proteins, in order to track the effectiveness of the TKI drugs. The instrument used fixes proteins in place and holds them, there allowing for a better signal to be generated from less material. With this approach they found that they could record changes in samples of only a few thousand critically important but rare stem cells.
“This new approach will enable us to test drugs on cells taken from patients, either at presentation or in a clinical trial setting. It has great potential to allow us to implement precision medicine, where patients receive the most appropriate treatment to target their individual tumour,” added Professor Whetton.
Cancer is one of The University of Manchester’s research beacons - examples of pioneering discoveries, interdisciplinary collaboration and cross-sector partnerships that are tackling some of the biggest questions facing the planet.
Notes for editors
Media enquiries to:
Media Relations Officer
The University of Manchester
Tel: 0161 2758383